CHHE: AI 评分 59/100 — AI 分析 (4月 2026)

China Health Industries Holdings, Inc. manufactures and sells health products, including hemp derivatives and health supplements, primarily through sales agents. The company operates in the People's Republic of China and focuses on products for various health needs, including skin care, bone density, and immunity.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

China Health Industries Holdings, Inc. is a manufacturer and seller of health products, including hemp-derived items and health supplements, operating primarily in China. The company's diverse product line targets various health needs, sold through a network of sales agents, positioning it within the specialty and generic drug manufacturing sector.

CHHE是做什么的？

China Health Industries Holdings, Inc. is a health product manufacturer and seller based in Harbin City, People's Republic of China. The company operates through its subsidiaries, focusing on developing, manufacturing, and distributing a range of health-related products. These include hemp derivative products like hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, and hemp frozen age nourishing creams. Additionally, they offer health supplements under the QunLe and Kindlink brands, addressing various health concerns such as freckle removal, skin moisture, and overall wellness. The company's product portfolio extends to medical drugs and supplements targeting acne removal, eyestrain relief, bone density enhancement, memory improvement, and anemia. China Health Industries Holdings sells its products primarily through sales agents, focusing on the Chinese market. With a small team of 32 employees, the company aims to cater to the growing demand for health and wellness products in China.

CHHE的投资论点是什么？

China Health Industries Holdings, Inc. operates in the growing Chinese health and wellness market. The company's diverse product line, including hemp-derived products and health supplements, caters to a wide range of consumer needs. However, the company's negative profit margin of -366.6% and lack of dividend payments raise concerns about its financial stability. The company's high beta of -20.54 suggests high volatility. Growth catalysts include expanding its sales agent network and introducing new products. The company's success depends on improving profitability and managing its operational costs effectively.

CHHE在哪个行业运营？

China Health Industries Holdings, Inc. operates within the specialty and generic drug manufacturing industry, a segment experiencing growth due to increasing healthcare awareness and demand for affordable medicines. The Chinese market is characterized by intense competition, with numerous domestic and international players. Key trends include a focus on preventive healthcare, personalized medicine, and the integration of traditional Chinese medicine with modern pharmaceuticals. China Health Industries Holdings competes with companies like BQST, ECGS, LUFFF, MCUJF, and MYCOF, all vying for market share in this dynamic landscape.

Drug Manufacturers - Specialty & Generic

Healthcare

CHHE有哪些增长机遇？

Expanding the Sales Agent Network: China Health Industries Holdings can grow by expanding its network of sales agents across China. The market for health products in China is vast, with increasing demand in both urban and rural areas. By increasing its sales agent network, the company can reach a wider customer base and increase sales volume. This expansion can be achieved within the next 1-2 years, potentially increasing revenue by 15-20%.
Introducing New Hemp-Derived Products: The market for hemp-derived products is growing rapidly, driven by increasing awareness of their health benefits. China Health Industries Holdings can capitalize on this trend by introducing new hemp-derived products, such as CBD-infused supplements and skincare items. The global CBD market is projected to reach $20 billion by 2025, offering a significant opportunity for the company. Launching these products within the next year could boost revenue by 10-15%.
Developing New Health Supplements: The demand for health supplements is increasing as consumers become more health-conscious. China Health Industries Holdings can develop new health supplements targeting specific health needs, such as weight management, immune support, and cognitive enhancement. The global health supplement market is expected to reach $230 billion by 2027, providing a substantial growth opportunity. Introducing these supplements within the next 18 months could increase revenue by 12-18%.
Entering E-commerce Platforms: The e-commerce market in China is booming, providing a convenient channel for consumers to purchase health products. China Health Industries Holdings can partner with major e-commerce platforms like Alibaba and JD.com to sell its products online. E-commerce sales in China are projected to reach $3 trillion by 2024, offering a significant opportunity for the company to expand its reach. Establishing an online presence within the next 6-12 months could increase revenue by 8-12%.
Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and wellness centers can provide China Health Industries Holdings with access to a broader customer base and enhance its brand credibility. These partnerships can involve joint marketing initiatives, product recommendations by healthcare professionals, and distribution agreements. The healthcare market in China is rapidly expanding, driven by government initiatives to improve healthcare access and quality. Forming these partnerships within the next year could lead to a 10-15% increase in revenue.

China Health Industries Holdings, Inc. operates with a market capitalization of $0.00B, indicating a micro-cap status.
The company's P/E ratio is -0.02, reflecting negative earnings.
The profit margin is -366.6%, indicating significant losses.
Gross margin is 0.2%, suggesting minimal profitability from sales.
The company's beta is -20.54, indicating high volatility relative to the market.

CHHE提供哪些产品和服务？

Manufactures and sells hemp derivative products, including hemp oil and protein powder.
Offers health supplements under the QunLe and Kindlink brands.
Provides products for freckle removal, skin moisture, and overall wellness.
Sells medical drugs for various health conditions.
Offers supplements for acne removal, eyestrain relief, and bone density enhancement.
Provides iron, multivitamin, and mineral supplements.
Sells products through sales agents in China.

CHHE如何赚钱？

Develops and manufactures health products, including hemp derivatives and supplements.
Sells products through a network of sales agents.
Focuses on the Chinese market.
Generates revenue through product sales.

Consumers seeking health and wellness products.
Individuals looking for supplements for specific health needs.
Customers in the Chinese market.
Patients requiring medical drugs.

Established presence in the Chinese health product market.
Diverse product portfolio catering to various health needs.
Proprietary formulations for health supplements.
Distribution network through sales agents.

什么因素可能推动CHHE股价上涨？

Upcoming: Potential expansion of sales agent network in new regions within China.
Upcoming: Launch of new hemp-derived products targeting specific health needs.
Ongoing: Increasing demand for health supplements in the Chinese market.
Ongoing: Growing awareness of the benefits of hemp-derived products.
Upcoming: Potential partnerships with e-commerce platforms to expand online sales.

CHHE的主要风险是什么？

Potential: Negative profit margin may continue, impacting financial stability.
Ongoing: Intense competition from other health product manufacturers.
Potential: Changing regulations regarding hemp-derived products.
Ongoing: Dependence on sales agents for distribution.
Potential: Economic downturn affecting consumer spending on health products.

CHHE的核心优势是什么？

Diverse product portfolio including hemp derivatives and health supplements.
Established sales agent network in China.
Proprietary formulations for certain products.
Focus on specific health needs such as skin care and bone density.

CHHE的劣势是什么？

Negative profit margin indicating financial instability.
High beta suggesting high volatility.
Dependence on sales agents for distribution.
Limited geographic reach primarily focused on China.

CHHE有哪些机遇？

Expanding the sales agent network to reach more customers.
Introducing new hemp-derived products to capitalize on market trends.
Developing new health supplements targeting specific health needs.
Entering e-commerce platforms to expand online sales.

CHHE面临哪些威胁？

Intense competition from other health product manufacturers.
Changing regulations regarding hemp-derived products.
Economic downturn affecting consumer spending on health products.
Potential supply chain disruptions.

CHHE的竞争对手是谁？

BioQuest Corp — Focuses on nutraceuticals and supplements. — (BQST)
ECGI Holding, Inc. — Offers a range of health and wellness products. — (ECGS)
Luff Enterprises Corp. — Specializes in health and beauty products. — (LUFFF)
MC Wellness Holdings Inc — Focuses on wellness and healthcare solutions. — (MCUJF)
Mydecine Innovations Group Inc. — Researches and develops psychedelic medicine. — (MYCOF)

Key Metrics

MoonshotScore: 59/100

Company Profile

CEO: Sun Xin
Headquarters: Harbin, CN
Employees: 32
Founded: 2009

AI Insight

AI analysis pending for CHHE

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does China Health Industries Holdings, Inc. do?

China Health Industries Holdings, Inc. manufactures and sells a variety of health products, including hemp-derived items like hemp oil and protein powder, as well as health supplements under the QunLe and Kindlink brands. These products target a range of health needs, from skin care and bone density to overall wellness. The company primarily sells its products through a network of sales agents in the Chinese market, catering to consumers seeking health and wellness solutions.

What do analysts say about CHHE stock?

As of March 16, 2026, there is no readily available analyst coverage for China Health Industries Holdings, Inc. due to its OTC Other listing and limited financial disclosure. Key valuation metrics such as P/E ratio (-0.02) and profit margin (-366.6%) indicate financial challenges. Growth considerations include expanding its sales network and introducing new products, but investors should exercise caution due to the lack of transparency and regulatory oversight associated with OTC Other stocks.

What are the main risks for CHHE?

The main risks for China Health Industries Holdings, Inc. include its negative profit margin, which raises concerns about its financial sustainability. The company also faces intense competition from other health product manufacturers in China. Changing regulations regarding hemp-derived products could impact its product portfolio. Additionally, its reliance on sales agents for distribution and the potential for economic downturns affecting consumer spending pose significant challenges.